Yuhan/Viromed jointly to develop therapy for chronic granulomas.
Published: 2006-01-23 06:56:00
Updated: 2006-01-23 06:56:00
Yuhan signed an agreement with Viromed Inc., a biotech company of Korea, at the head office on Jan. 18 for a joint research and development of a gene therapeutic compound VM106 for the treatment of chronic granulomas, a hereditary immune deficiency disease.
Two parties by this joint agreement ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
